PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company, announced that its President and CEO, James McArthur, Ph.D., will present at the 22nd Annual Needham Virtual Healthcare Conference on April 20th, 2023, at 8:00 AM EDT. The presentation will be available for live streaming and will also be archived for one year on the company’s website. PepGen focuses on advancing next-generation oligonucleotide therapies aimed at severe neuromuscular and neurological diseases, utilizing its Enhanced Delivery Oligonucleotide (EDO) platform. This platform leverages over a decade of research to enhance the uptake and efficacy of oligonucleotide therapeutics through cell-penetrating peptides.

BOSTON, April 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, Ph.D., President and CEO of PepGen will present at the 22^nd Annual Needham Virtual Healthcare Conference on Thursday, April 20^th at 8:00am EDT.

The event will be webcast live under the Events & Presentations section of the Investor Relations section of PepGen’s website. A replay of the event will be archived for one year.

About PepGen
PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that target the root cause of serious diseases.

Investor Contact
Laurence Watts
Gilmartin Group
Laurence@gilmartinir.com  

Media Contact
Sarah Sutton
Argot Partners
PepGen@argotpartners.com

FAQ

What is PepGen Inc. and what do they specialize in?

PepGen Inc. is a clinical-stage biotechnology company specializing in the development of next-generation oligonucleotide therapies for severe neuromuscular and neurological diseases.

When will James McArthur present at the Needham Healthcare Conference?

James McArthur will present at the 22nd Annual Needham Virtual Healthcare Conference on April 20th, 2023, at 8:00 AM EDT.

How can I watch the PepGen presentation at the Needham Conference?

The presentation will be webcast live and available for replay in the Events & Presentations section of PepGen's website.

What is the Enhanced Delivery Oligonucleotide (EDO) platform?

The EDO platform is PepGen's innovative approach to improve the uptake and activity of oligonucleotide therapeutics, using cell-penetrating peptides.

Where can I find more about PepGen's investor information?

You can find more information about PepGen's investor relations on their official website.